Clinical trial
Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past…
NCT00203606 · University of Calgary, Other · Completed
Key facts
| NCT number | NCT00203606 |
|---|---|
| Title | Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C |
| Official title | Effectiveness of Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C |
| Lead sponsor | University of Calgary, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis c |
| Intervention type | Drug |
| Interventions | pegylated interferon alfa-2a ( Roche) and ribavirin |
| Enrollment | 66 |
| Start date | Jan 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Aug 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 4, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: